[HTML][HTML] Immune response to dengue and Zika

A Elong Ngono, S Shresta - Annual review of immunology, 2018 - annualreviews.org
Flaviviruses such as dengue (DENV), yellow fever (YFV), West Nile (WNV), and Zika (ZIKV)
are human pathogens of global significance. In particular, DENV causes the most prevalent …

Controlled human infection models to accelerate vaccine development

RKM Choy, AL Bourgeois… - Clinical Microbiology …, 2022 - Am Soc Microbiol
The timelines for developing vaccines against infectious diseases are lengthy, and often
vaccines that reach the stage of large phase 3 field trials fail to provide the desired level of …

Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents 2 years after vaccination

E López-Medina, S Biswal… - The Journal of …, 2022 - academic.oup.com
Background Takeda's dengue vaccine is under evaluation in an ongoing phase 3 efficacy
study; we present a 2-year update. Methods Children (20 099, 4–16 years old) were …

[HTML][HTML] Current development and challenges of tetravalent live-attenuated dengue vaccines

J Hou, W Ye, J Chen - Frontiers in Immunology, 2022 - frontiersin.org
Dengue is the most common arboviral disease caused by one of four distinct but closely
related dengue viruses (DENV) and places significant economic and public health burdens …

Clinical safety experience of TAK-003 for dengue fever: a new tetravalent live attenuated vaccine candidate

SS Patel, M Rauscher, M Kudela… - Clinical Infectious …, 2023 - academic.oup.com
Background An unmet medical need remains for an effective dengue tetravalent vaccine that
can be administered irrespective of previous dengue exposure. TAK-003, a dengue …

[HTML][HTML] A tetravalent sub-unit dengue vaccine formulated with ionizable cationic lipid nanoparticle induces significant immune responses in rodents and non-human …

G Swaminathan, EA Thoryk, KS Cox, JS Smith… - Scientific reports, 2016 - nature.com
Dengue virus has emerged as an important arboviral infection worldwide. As a complex
pathogen, with four distinct serotypes, the development of a successful Dengue virus …

Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial

V Tricou, X Sáez-Llorens, D Yu, L Rivera, J Jimeno… - The Lancet, 2020 - thelancet.com
Background An unmet clinical need remains for an effective tetravalent dengue vaccine
suitable for all age groups, regardless of serostatus. We assessed the immunogenicity and …

[HTML][HTML] Protective role of cross-reactive CD8 T cells against dengue virus infection

AE Ngono, HW Chen, WW Tang, Y Joo, K King… - …, 2016 - thelancet.com
Infection with one of the four dengue virus serotypes (DENV1-4) presumably leads to
lifelong immunity against the infecting serotype but not against heterotypic reinfection …

Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2 …

X Sáez-Llorens, V Tricou, D Yu, L Rivera… - The Lancet Infectious …, 2017 - thelancet.com
Background Dengue is the most common mosquito-borne viral disease in human beings,
and vector control has not halted its spread worldwide. A dengue vaccine for individuals …

A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone

JE Osorio, D Wallace, DT Stinchcomb - Expert Review of Vaccines, 2016 - Taylor & Francis
Dengue fever is caused by infection with one of four dengue virus (DENV) serotypes (DENV-
1–4), necessitating tetravalent dengue vaccines that can induce protection against all four …